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Background: Endoscopic surveillance has been proven effective in prolonging the survival of gastric cancer (GC)
patients. However, there is limited evidence on the cost efficiency of delivering this intervention, especially on a
national level in spite of cost efficiency being a major determinant of the actual cost-effectiveness of a cancer
prevention programme. The Singapore Gastric Cancer Epidemiology Clinical and Genetic Programme (GCEP) is a
demonstration project offering scheduled endoscopy to the Chinese population aged 50 years or older in
Singapore.
By assessing the cost efficiency of the GCEP, this study aimed to provide empirical evidence on the cost structure
and mechanisms underlying cost generation in conducting GC surveillance, thus informing resource allocation and
programme budgeting for the Singapore government.
Methods: From a societal perspective, we reported on the direct cost (resource consumption) of conducting
endoscopic surveillance through the GCEP network. We retrospectively collected individual-level data of 216
subjects recruited at the National University Hospital, Singapore from 01/04/2004 to 31/10/2010. The Overall Cost,
Clinical Cost, GCEP Cost and Personal Cost incurred in serving one subject was computed and discounted as 2004
US dollar (US$) per capita for every year. The Generalized Estimation Equation (GEE) was used to model the data.
Results: All cost indices continuously declined over the 6.5-year costing period. For the total sample, Overall Cost,
Clinical Cost, GCEP Cost and Personal Cost declined by 42.3%, 54.1%, 30% and 25.7% respectively. This downward
trend existed for age and gender subgroups and the high risk group only with cost reductions varying between
3.5% and 58.4%. The GEE models confirmed statistical significance of the downward trend and of its association
with risk profile, where the moderate risk group had cost indices at most 77% of the high risk group.
Conclusions: Our study offered empirical evidence of improved cost efficiency of a surveillance programme for GC
in the early phase of programme implementation. Mechanisms such as economies of scale and self-learning were
found to be involved in the cost reduction. Our findings highlighted the importance of assessing the cost efficiency
and offered valuable insights for future programme budgeting and policy making.
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In the global campaign to eradicate gastric cancer (GC),
which claims over 700,000 lives every year [1], screening
has assumed a paramount role but not without limitations
[2]. Even in Japan, the country with the highest incidence
of GC, the cost-effectiveness of national GC screening is
fading away due to the decrease in incident cases [3]. Con-
sidering the worldwide declining trend of GC incidence
over the past two decades [4], screening at the national
level may not be the optimal strategy for GC eradication.
Therefore, GC surveillance targeted at high risk subpo-
pulations offers a complementary or alternative strategy
given that hospital-based GC surveillance has already dem-
onstrated its efficacy in detecting cases at early stages of
cancer development [5,6]. Surveillance is also sensible for
industrialized countries with overall very low GC incidence
because of specific ethnic groups such as Asian immigrants
among whom GC remains a major disease burden [7,8].
The Gastric Cancer Epidemiology Clinical and Genetic
Programme (GCEP) is an endoscopic surveillance pro-
gramme targeted at the Chinese population aged 50 years
or above in Singapore, a country with an intermediate risk
of GC [9]. The GCEP target population has a GC inci-
dence much higher than the general population [10].
Based on the preliminary explorations of GC endoscopic
screening [11], the GCEP was intended to inform the
feasibility and benefit of GC surveillance as a control strat-
egy for GC in Singapore. The GCEP system is established
in four local general hospitals and has been running since
2004. Its surveillance follow-up is incorporated into the
daily work routine of the participating hospitals.
Cancer prevention programmes are costly undertakings
and are featured by many years or even decades of time-
lag between investment and the desired outcome. This
then raises an important issue of cost efficiency - whether
the programme is producing the service at the least cost,
i.e., the lowest price per unit of service. Cost efficiency is
one of major determinants of actual cost-effectiveness de-
livered by a specific programme [12]. However, to date,
most cost analyses on cancer prevention have been cross-
sectional studies which may have lead to skewed or biased
cost estimates [13-15]. A survey-based top-down approach
for data collection adopted in these studies is also prone
to subjectivity [16]. The time-lag effect and long-term fol-
low up associated with cancer prevention entails the un-
derstanding of continuous cost generation which a cross-
sectional study is unable to address. Furthermore previous
studies have not investigated the clinical cost, the patient
personal cost and the programme associated cost in the
same study, and are thus limited in providing a more de-
tailed and complete description of the broader economic
impact of the programme [17-21].
With the above considerations, a trial programme such
as the GCEP is the ideal vehicle to empirically exploreand evaluate the cost efficiency of GC surveillance.
Evaluating the GCEP would be very informative for a fu-
ture cost-effectiveness analysis of GC surveillance in
Singapore and would have direct relevance to government
budgeting. This will prevent incomplete information from
affecting optimal resource allocation decisions. Thus, we
designed this study with the aims of 1) informing resource
allocation and programme budgeting in the planning of
national surveillance of GC in Singapore; 2) providing a
comprehensive cost structure for full economic evaluation
of GC surveillance both locally and worldwide; 3) elucidat-
ing the mechanisms underlying cost generation of cancer
surveillance programmes. This information will be of
value to health administrators and planners in planning
similar programmes, as well as providing a framework for




The GCEP is an ongoing trial surveillance programme with
the aim of eventually becoming a government-organized
GC surveillance programme. The most pertinent concern
about establishing such a programme is the financial im-
pact on society by the programme. Therefore, this study
was conducted from a societal perspective, whereby the
direct costs on GCEP (the healthcare provider) and the pa-
tients (the beneficiaries) in undertaking GCEP surveillance
were measured by a bottom-up approach and reported as
US dollars per person served [22].
Service mix of the GCEP programme
According to the GCEP Protocol Version 7, once a sub-
ject was recruited, the 5-year annual follow-up would be
customized to the individual’s risk of developing GC
assessed at baseline. Those fulfilling any of five criteria,
namely (1) dysplasia, (2) intestinal metaplasia, (3) atro-
phic gastritis, (4) GC family history, and (5) presence of
H. pylori infection were categorized as high risk subjects
and underwent annual oesophago-gastro-duodenoscopy
(OGD) examination. All other subjects were classified as
moderate risk and underwent OGD in Years 3 and 5
with telephone interviews or clinic visits in Years 1, 2,
and 4. If patients were unable to be present for endos-
copy, they were contacted by telephone for GC related
symptoms. The primary outcome was the detection of
early gastric cancer or high grade dysplasia.
Study site, period & sample
The GCEP consists of a decentralized service network
involving the National University Hospital (NUH), Tan
Tock Seng Hospital, Singapore General Hospital and
Changi General Hospital in Singapore. This study used
data from the NUH only, as it is a tertiary medical
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can be divided into three distinctive phases: Start-up,
Full-Implementation and Closeout [22], with each phase
encompassing different activities (Additional file 1).
Compared to the Start-up and Closeout phases, the Full
Implementation phase (01/04/2004 – 31/12/2010) cap-
tured most of the cost-intensive activities, and thus
closely reflected cost generation assuming the GCEP was
officially implemented on a national scale. Therefore this
study chose the first 6.5 years from 01/04/2004 to 31/10/
2010 of the Full Implementation phase as the costing
period. To ensure a minimum 2-year follow-up for every
subject, we concentrated our analysis on the cohort
recruited between 01/04/2004 and 31/03/2008 (n = 749),
from which a random sample of 216 cases (29%) was
drawn through proportionate stratified sampling by age,
gender and risk profile.
Resource quantification and costing
A task force funded solely by the GCEP grant was
established at the NUH to exclusively operate the
programme. The GCEP as the service provider paid the
NUH for clinical, logistic and financial services. A co-
payment system was also applied for clinical services
whereby the GCEP provided free follow-up endoscopy,
histology/biopsy and urease testing and patients were liable
for baseline endoscopy, medication, consultation and diag-
nostic tests prescribed at follow-ups (Additional file 2).
From the NUH GCEP database, we retrospectively
identified and quantified the resources consumed by a
single subject at baseline and subsequent follow-ups by
reviewing clinical casenotes and GCEP financial state-
ments. Data sources of cost information included the
Land Transportation Authority, Ministry of Manpower
and the NUH financial office. The costs of each GCEP
service were estimated by multiplying the quantities of
various resources with the best-available unit cost for
that resource. The cost components and estimation
methods are summarized in Table 1.
As this study was conducted in 2010, the unit costs of
clinical items were based on actual hospital charges at
that time. Although hospital charges may not truly rep-
resent the cost of the services provided, these were the
only data available. Considering that NUH is a not-for
-profit public healthcare institution with most charges
being set based on the principle of cost recovery, the use
of charges in this instance would be a reasonable reflec-
tion of actual costs.
Non-clinical GCEP resources included capital, over-
head costs, consumables and manpower, of which only
yearly total expenditures were available. Equipment, par-
ticularly computers, was the major capital outlay for the
GCEP. Therefore the 5-year useful life of a computer
was used to calculate the annual equivalent of capitalcost [23]. The overhead cost was a 20% increment of
cash flow charged every year by the NUH to cover the
office space, utilities, logistics and other services. The
total amount of the GCEP staff salaries was used to esti-
mate the cost of manpower. Unlike clinical resources,
for which the consumption was recorded individually in
the casenotes, non-clinical resources were shared by all
the subjects served during a given period. Thus the cost
of the non-clinical items, the so called ‘programme cost’
were directly allocated to each subject [17,22]. Given
that the telephone interview, clinic visit and OGD examin-
ation consumed different amounts of time and non-
clinical resources, they were assigned as ‘1’, ‘2’ and ‘3’ unit
weight respectively to reflect the relative utilization of
these resources. The programme cost was then assigned
to each subject based on their individual weights. Care-
giver time refers to when patients were accompanied by a
person other than a nurse to the NUH.
Outcomes
All individual items were categorized into four compo-
nents, from which primary outcomes originated for this
study (Table 1). These outcomes comprised four cost in-
dices that were informative and essential to future cost-
effectiveness analysis and programme budgeting [24].
These indices (expressed as US$ per capita) were: 1)
Overall Cost (which includes Patient Clinical, Patient
Non-clinical, GCEP Clinical and GCEP Non-clinical)
quantifying the overall resource consumption; 2) Clinical
Cost (which includes Patient Clinical and GCEP Clinical)
quantifying the consumption of clinical resources; 3)
GCEP Cost (which includes GCEP Clinical and GCEP
Non-clinical) quantifying the economic burden on the
health care provider – the GCEP; and 4) Personal Cost
(which includes Patient Clinical and Patient Non-clinical)
quantifying the cost for a subject to receive GCEP ser-
vices. These cost indices were presented in 2004 US dol-
lars with 3% discount rate [25].
Statistical analysis
All four cost indices were computed for each subject in
every financial year within the costing period. The Student’s
t-test, Chi-Square test and survival analysis were used to
compare continuous variables, categorical variables and
rates between the sample and the cohort respectively. Since
economic data are generally right-skewed and right-
censored [26], this study used the semi-parametric boot-
strapping method (n = 1000) to calculate standard errors.
The data in each year of the same subject was correlated
across follow-up time. To adjust for this within-subject cor-
relation, the multivariate Generalized Estimation Equation
(GEE) was used to model the data and to quantify and test
the potential temporal trends in outcome indices. Due to
the co-payment system, the temporal trends of the GCEP
Table 1 Cost components and cost estimation of the GCEP (NUH) (2004–2010)
Components Items Estimate methods Data source Resource quantification (per GCEP service) *unit cost
Patient
Clinical Medications Micro-costing Casenotes & NUH Name & dosage of medication Price charged by NUH
Consultation Case-mix Casenotes & NUH Specialist consultation within 3 months after OGD Mean charge by NUH
Diagnostic test Case-mix Casenotes & NUH Tests prescribed at follow-up Mean charge by NUH
Histology Case-mix Casenotes & NUH Biopsy during OGD Mean charge by NUH
Endoscopy Case-mix Casenotes & NUH Baseline & opportunistic OGD Mean charge by NUH
Non-clinical Transportation National Mean Casenotes & LTA Round trip with mean mileage Taxi fare based on mileage by year
Patient time Human capital approach Casenotes & MOM One day prescribed Median age-gender specific wage by year
Caregiver time Human capital approach Casenotes & MOM One day prescribed Median gross wage by year
GCEP
Clinical Endoscopy Case-mix Casenotes & NUH Endoscopy & related procedure Fixed charge negotiated with NUH
Histology Case-mix Casenotes & NUH Biopsy during OGD Fixed charge negotiated with NUH
Urease Case-mix Casenotes & NUH Urease test during OGD Fixed charge negotiated with NUH
Doctor’s time for OGD Case-mix Casenotes & NUH Mean duration for OGD Mean salary/minute
Non-clinical Consumables Direct allocation Project record Total spending/caseload
GCEP staff Direct allocation Project record Total salary/caseload
Overhead Direct allocation Project record Total spending/caseload
Capital Direct amortization and allocation Project record Annual equivalent/caseload
NUH, National University Hospital; OGD, oesophago-gastro-duodenoscopy; LTA, Land Transportation Authority; MOM, Ministry of Manpower.




















Table 2 Characteristics of the study cohort and sample
Cohort* (n = 749) Sample* (n = 216) P
Age (year) 60.13 (7.32) 7.32 (60.23) 0.86†
Age group 50-59 years 426 (56.88) 121 (56.02)
≥ 60 years 323 (43.12) 95 (43.98) 0.88‡
Gender Male 401 (53.54) 123 (56.94)
Female 348 (46.46) 93 (43.06) 0.39‡
Risk profile Moderate 211 (28.17) 59 (27.31)
High 538 (71.83) 157 (72.69) 0.86‡
Follow-up (year) 3.34 (1.28) 3.55 (1.22) 0.03 †
Outcome EGC 6 (0.8) 1 (0.46)
Death 7 (0.93) 2 (0.93)
Drop-out 49 (6.54) 8 (3.70)
Survival 687 (91.73) 205 (94.91) 0.47‡
Incidence Rate‖ 240 (108, 534) 131 (18, 930) 0.98 §
Death Rate‖ 280 (133, 587) 262 (66, 1048) 0.978 §
Drop-out Rate‖ 1959 (1481, 2592) 1049 (524, 2097) 0.831 §
Abbreviation: EGC: early gastric cancer.
* Values are the mean (SD) for continuous variables and n (%) for categorical variables. Rates are reported with 95% confidence interval.
† Student t-test.
‡ Chi-Square test.
§ Fisher’s exact test based on rate difference.
‖ Unit of rates is 1/100,000 per year.
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was included in the analysis. Hence, we excluded the base-
line data from the analysis of these two indices. As year
2004 had only baseline OGDs, the data from this year was
not presented in the results of the GCEP Cost and PersonalFigure 1 Temporal trends (2004–2010) of cost indices for the whole s
follow-up year.Cost. Statistical analyses were performed using SPSS (ver-
sion 19; SPSS, Inc, Chicago, IL), STATA version 10 (Stata
Corporation, TX) and Microsoft Excel 2007 (Microsoft,
Redmond, WA). A p-value of 0.05 was used for significance
for all statistical analyses.ample. Individual points represent the means of cost indices in each
Figure 2 Temporal trends (2004–2010) of mean cost indices for the age subgroups. Individual points represent the means of cost indices
in each follow-up year.
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The study sample adequately represented the NUH
GCEP cohort (Table 2). With the exception of the
follow-up time, which was 2.5 months longer for the
study sample (p = 0.03), the sample and cohort were
homogenous with respect to demographics, patient out-
come and event rates with non-significant p values.
The cost efficiency of the GCEP improved over time. As
shown in Figure 1, the monetary value of all four cost in-
dices declined throughout the 6.5-year costing period.
Despite variations over time, the downward trends of the
cost indices were apparent from the onset of the GCEP.
The mean Overall Cost of serving one subject steadily de-
clined by 42.3% from US$1025 in 2004 to US$591 in 2010.
The Clinical Cost, GCEP Cost, and Personal Cost also de-
clined by 54.1%, 30% and 25.7% over this period respect-
ively. The difference in magnitude of cost reduction is the
result of the reductions of the cost components constitut-
ing each index.
As age and gender are critical for defining the target
population for GC surveillance, the downward trends of
the cost indices were further investigated in the age (50–
59 year vs. ≥ 60 year) and gender (male vs. female) sub-
groups. In Figures 2 and 3, cost indices experienced a slow
and steady decline in all four demographic subgroups as
they did in the whole sample. Across the four groups, the
Overall Cost dropped by between 40% and 47%. The Clin-
ical Cost dropped by 52.1% to 58.4% and the GCEP Cost
dropped by between 23% and 39%. The Personal Cost hadthe least percentage drop of 3.5% for the age group 50–59 -
years, and the biggest drop of 43% for the age group ≥ 60 -
years. The downward trends were demonstrated to be
consistent for age and gender subgroups. Furthermore,
Figures 2 and 3 illustrated that the curves representing
subgroups based on age or gender overlapped to a large
extent and were almost identical, suggesting that resource
consumption was not associated with a subject’s age or
gender.
As per protocol, risk assessment at baseline determines
the number of OGD which a GCEP subject will take dur-
ing follow-up and is an important modifiable factor for re-
source allocation. As expected, the risk profile had a big
impact on cost indices for the two risk groups. In Figure 4,
the cost curves for the high risk group ran above those of
the moderate risk group for all cost indices, illustrating
that the high risk subjects consumed more resources than
the moderate risk subjects. The Overall Cost, Clinical
Cost, GCEP Cost and Personal Cost of the moderate risk
group accounted for 77%, 68.1%, 60% and 65.1% of the
high risk group respectively.
Risk profile also affected the downward trend pattern.
The temporal trends were not universally downward for
the three pairs of risk groups or for all cost indices
(Figure 4). The Overall Cost and Clinical Cost retained
their downward trends for both the high risk and mod-
erate risk groups. However, the GCEP Cost and Personal
Cost differed dependent on the risk profile. On average,
the GCEP Cost to serve one subject at the high risk
Figure 3 Temporal trends (2004–2010) of mean cost indices for the gender subgroups. Individual points represent the means of cost
indices in each follow-up year.
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moderate risk subject over the costing period. Similarly,
the Personal Cost paid by a single high risk subject
dropped by 36.5%, while it increased by 76.1% from US
$46 in 2005 to US$81 in 2010 in moderate risk subjects.Figure 4 Temporal trends (2004–2010) of cost indices for the risk sub
follow-up year.The GEE models fitting the temporal trends of cost in-
dices and the comparison of the trends between the
three pairs of subgroups of age, gender and risk profile
are presented in Table 3. Twenty six out of 28 GEE
models in Table 3A confirmed the downward trends asgroups. Individual points represent the means of cost indices in each
Table 3 GEE models fitting temporal trends of cost indices and comparison of subgroup trends
Overall cost Clinical cost GCEP cost Personal cost
Mean 95% CI P Mean 95% CI P Mean 95% CI‡ P Mean 95% CI‡ P
A: Temporal trends
Whole Sample* −106 (−117, -95) < 0.001 −40 (−46, -34) < 0.001 −48 (−63, -34) < 0.001 −9 (−12, -4) < 0.001
Age (year) * 50-59 −109 (−124, -94) < 0.001 −41 (−49, -33) < 0.001 −40 (−60, -19) < 0.001 −7 (−12, -1) 0.01
> = 60 −102 (−117, -87) < 0.001 −37 (−47, -28) < 0.001 −59 (−78, -39) < 0.001 −10 (−15, -5) < 0.001
Gender* Male −101 (−115, -87) < 0.001 −37 (−45, -29) < 0.001 −44 (−62, -26) < 0.001 −7 (−12, -1) 0.009
Female −112 (−131, -93) < 0.001 −43 (−53, -34) < 0.001 −54 (−77, -32) < 0.001 −10 (−15, -4) 0.001
Risk Profile* High −112 (−123, -100) < 0.001 −43 (−49, -36) < 0.001 −73 (−87, -60) < 0.001 −13 (−17, -10) < 0.001
Moderate −46 (−61, -32) < 0.001 −18 (−28, -7) 0.001 26 (3, 49) 0.027 5 (−3, 14) 0.212
B: Comparisons between subgroups
> = 60 year vs. 50-59† 21 (−23, 65) 0.36 17 (−5, 40) 0.127 34 (−17, 84) 0.188 4 (−11, 18) 0.634
Male vs. Female† 10 (−35, 54) 0.675 1 (−21, 22) 0.965 15 (−34, 65) 0.536 7 (−8, 21) 0.382
High vs. Moderate† 192 (155, 228) < 0.001 87 (68, 104) < 0.001 226 (190, 263) < 0.001 39 (26, 52) < 0.001
Abbreviations: C.I., confidence interval.
* Means are average decrement/increment across costing period.
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p values and negative annual change in monetary values.
Only two GEE models fitting the GCEP Cost and Personal
Cost for the moderate risk group suggested a cost increase
over the follow-up period. Comparative analysis of the
cost trends in the subgroups revealed how other factors af-
fected resource allocation. Significant results were only
found when more resources were allocated to the high risk
group than to the moderate risk group (Table 3B). There
were no significant differences in annual expenses within
age or gender subgroups.
Discussion
To the best of our knowledge, studies about continuous
cost generation of cancer prevention programmes have
not been previously reported despite that many studies
have acknowledged the limitations of cross-sectional
cost estimates. Our study attempts to fill this gap. The
gradual and continuous decline of cost indices in our
study strongly indicated the ever-improving cost effi-
ciency of endoscopic surveillance for GC through the
GCEP during the observation period. This study as a
free standing cost analysis, despite its inability to com-
pute the cost-effectiveness ratio, provided important em-
pirical evidence for programme management and
ultimately for value-for-money decision making. Cost
studies of long-term GC surveillance have long been an-
ticipated worldwide given that research already illus-
trated the benefit of GC surveillance [27,28]. Exploring
the mechanisms underlying our results would be of uni-
versal interest to GC researchers.
Economy of scale is considered the main reason for
the cost reduction, especially for the Overall Cost and
the GCEP Cost [16,17]. Previous studies have shown
that as the screening volume increased, the average cost
borne by the health care provider to serve one subject
decreased, thereby approximating an inverse relationship
[29]. The GCEP has experienced a 7-fold increase of
patient volume from 175 in 2004 to 1223 in 2009. Con-
sequently the average cost decreased because fixed costs
spread out horizontally across the number of subjects
served every year and vertically along the implementa-
tion time. Correlation analysis showed a negative correl-
ation coefficient between workload and Overall Cost and
GCEP Cost, with the former achieving statistical signifi-
cance (r = −0.821, p = 0.023).
More efficient utilization of the resources within the
GCEP system was another factor driving the GCEP Cost
down. It is well known that public health programmes can
improve operational efficiency through self-learning [15],
which would in return lead to decreased costs borne by
the service provider. Having been in operation for seven
years and with quality assurance protocols in place, the
GCEP could optimize work-flow processes by shorteningwaiting times, avoiding repetitions and enhancing service
awareness in team members [30]. Although specific pa-
rameters were not set to gauge its work-flow processes, it
was fair to assume that the self-learning mechanism took
effect, especially in the inception of the Full Implementa-
tion phase which was the costing period of our study.
The decline in Clinical Cost indicated that subjects con-
sumed less of the clinical services, which consist of follow-
up OGD, specialist consultations, diagnostic tests and
medications (Table 1). This is most likely due to a reduced
demand of clinical services in later follow-ups when the
subjects were experiencing fewer symptoms as a result of
surveillance and associated treatment. Our findings were
consistent with a cost study of a colorectal cancer screen-
ing programme which showed that repeated screenings
cost less than initial screenings because of the lower
prevalence of disease in the rescreening group as opposed
to first-time participants [31]. Congruent with the previ-
ous observation, the Personal Cost also decreased as pa-
tients paid less for clinical services.
A further reason for the Personal Cost reduction was
the declining price of patient time estimated by the hu-
man capital approach [32], whereby the opportunity cost
of taking one day off work for an OGD or clinic visit
was measured as a single day’s salary. In Singapore, there
was a large decrease in salary from the age group 50–59 -
years to the age group 60 years or above [33]. As one of
the GCEP inclusion criteria was being age 50 years old
or above, we noted that during the observation period,
42 subjects (19.4%) underwent the age change from 50–
59 years old to 60 years old and above.
Subgroup analysis was conducted to explore the cost
generation in subgroups categorized by age and gender,
which are relevant to the diagnostic yield of a screening
programme [34,35]. Similar to the observation for the
whole sample, both gender subgroups experienced sig-
nificant annual decreases with bigger decrements in fe-
males for all four cost indices (Table 3). As for the
impact of age, compared with subjects 60 years or older,
subjects between 50 and 59 years had a larger decrement
in Overall Cost and Clinical Cost, US$109 vs. US$102
and US$41 vs. US$37 respectively, and a smaller decre-
ment in the GCEP Cost and Personal Cost, US$40 vs.
US$59 and US$7 vs. US$10 respectively (Table 3). Com-
paring the average costs of the subgroups for either vari-
able failed to reveal significant differences, as illustrated
by the overlapping curves in Figures 2 and 3. The cost
efficiency in subgroups as described above was of great
significance in advising resource distribution among
these subgroups and in computing population specific
cost-effectiveness ratios subsequently.
As the cost-effectiveness of screening is sensitive to dis-
ease incidence in target populations [11,36], the GCEP clas-
sified subjects into high and moderate risk of GC, which
Zhou et al. BMC Health Services Research 2013, 13:139 Page 10 of 12
http://www.biomedcentral.com/1472-6963/13/139subsequently determined the frequency of surveillance
OGD. The temporal trends of cost indices were statistically
different between high and moderate risk groups (Figure 4
and Table 3). The Overall Cost and the Clinical Cost for
the high risk group had annual decrements 2.4 times lower
than those for the moderate risk group. The GCEP Cost
and Personal Cost showed a downward trend in the high
risk group, while they both increased over time in the
moderate group. The cost difference between high and
moderate risk groups was arbitrary as OGD frequencies
were decided beforehand, yet it has implications for
funding and for evaluating the cost-effectiveness of a spe-
cific population.
Compared to other published cost-analyses of cancer
screening programmes, our study was unique in four
ways, in that we 1) analyzed long-term continuous cost
generation; 2) collected individual-level data; 3) identified
and quantified all possible resources; and 4) studied mul-
tiple indices simultaneously. The advantages of these are
discussed as follows.
Given that long-term or life-long follow-up is required in
a cancer surveillance programme we studied a prospective
cohort, the GCEP, with 6.5-year follow-up data and
reported on the temporal trends of cost indices, in addition
to the point estimates which are the sole outcomes in
cross-sectional studies [13,17]. There is a high likelihood
that point estimates are skewed or biased depending on
the period chosen in a specific study [14,37]. Programme
activities and patient volume varied greatly from year to
year resulting in inflated/deflated point estimates [13,38].
Our study, rather than overestimating/underestimating the
cost values, reported on the temporal variation of costs
that can be used to predict the variability and the evolution
of the cost - two aspects crucial for programme budgeting.
Regarding the quality of data, our study collected
individual-level data based on the NUH GCEP database.
The quality of our data afforded statistical advantages over
aggregate data analyzed in other studies [13,39]. Individual-
level data captured person-to-person and year-to-year
variations which allowed us to estimate the means and
confidence intervals from actual distributions and to
apply GEE models, thereby enhancing the validity and re-
liability of our results.
In addition, we used the original documents of patient
casenotes and the GCEP financial statements to identify
clinical and non-clinical items directly associated with
programme operation. A bottom-up approach was adopted
to quantify resources consumed and to estimate their
monetary value [22,40], thereby avoiding subjectivity or
recall bias when data is collected through a survey-based
top-down approach [15], and ensuing high accuracy and
completeness of the data.
A major contribution of our study was that we simultan-
eously investigated multiple cost indices, each of whichhas been a focus in separate previous studies [13,16,32,41].
To our knowledge, no study has investigated these indices
simultaneously in a single study thereby overlooking the
fact that these costs accrued concurrently. Complete and
accurate cost data are crucial to both an economic evalu-
ation and programme planning. Economic evaluations
tend to underestimate the cost because of poor represen-
tation of personal costs and programme costs [42]. The
personal cost represents the financial commitment of a
subject to participate in screening [20,41], so it was associ-
ated with subject compliance and programme effective-
ness [43,44]. Our study found that patients paid at the
most 18.2% of what was borne by the service provider (the
GCEP) (Figure 1), suggesting that the co-payment could
be a viable arrangement. Programme cost measures the
expenditure on non-clinical activities and represent the
internal resource allocation within programmes. A cost
analysis of a colon cancer screening programme demon-
strated that non-clinical activities consumed more than
50% of the total budget [17], exceeding the US federal
standard of 40% [45]. In our study, the Clinical Cost
accounted for only 17.35% to 35.76% of the Overall Cost,
i.e., the non-clinical cost ranged between 64.24% and
82.65% (Figure 1). Although this study took a societal per-
spective and applied a narrower definition of clinical ser-
vice, as an organized surveillance programme in a small
country such as Singapore, a high proportion of non-
clinical expenditure appealed to the more efficient internal
resource allocation.
We acknowledge several limitations with our study. As
a pure cost analysis, this study is inherently unable to in-
form the value-for-money decision which is of utmost
importance yet requires a full economic evaluation. In
addition, service underutilization which is negatively as-
sociated with programme effectiveness, cannot be ruled
out as a mechanism driving down the cost in our study.
The co-payment system whereby patients are committed
to a certain amount of money could impede some patients
from using GCEP services, especially those from low-
income families [18,44,46]. Removal of patient costs has
been demonstrated to increase the screening compliance
[47]. Retrospective data collection in the current study
cannot accurately match the cost with the specific clinical
or administrative activities. Therefore, we could not iden-
tify the area of inefficiency. As for the Personal Cost, we
may have omitted some elements which could only be re-
trieved through personal interview. Furthermore, caution
is needed to extrapolate the downward trends beyond the
observation period, because all the factors accounting for
the cost reduction have limits [17]. Nonetheless, our re-
sults confirmed continuous cost decrements in the early
phase after full implementation. However, data seemed to
indicate that the descending momentum has stopped in
2009 (Figures 1, 2, 3 and 4). The ideal situation is that a
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tions on its minimum average cost curve [16]. A measure
of a successful programme is how soon this point is
reached, however this was not captured in our study.
Conclusion
Our study highlighted the importance of assessing the cost
efficiency of a pilot project for future economic evaluation
and government planning. The downward trends in cost
indices and the factors contributing towards them offered
valuable insights for future programme budgeting and pol-
icy making. It is crucial for health administrators and plan-
ners to identify these factors and to further maximize their
effect on cost efficiency in order for their programmes to
succeed. Furthermore, our study illustrated the distinct
pattern of resource consumption and its temporal vari-
ation in individual subgroups classified by variables defin-
ing the target population. These findings call for accurate
classification of the target population and for the compu-
tation of a population specific cost-effectiveness ratio.
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